Recommendation of the President – Emcitate (tiratricol)

On 22 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 92/2025 on the validity of granting approval for reimbursement of the medicinal product Emcitate (tiratricol) for the indication: Allan-Herndon-Dudley syndrome

Publication in Public Information Bulletin (BIP) >>